Given that PTEN is involved in both tamoxifen-resistance and trastuzumab-resistance [48–50], more studies are needed to validate whether MTDH is a general or a specific mechanism of drug resistance and how it functions in breast cancer. The gene discussed is PTEN; the disease is breast carcinoma.